The ACME Laboratories Ltd. — Company profile

Pharmaceutical Preparations · Bangladesh

Last price 77.9 BDT (At close: Oct 29, 2026) · Market cap 16.48B

Latest research: The ACME Laboratories valuation report: fair value BDT 64.9–137 (Oct 2026) · ACME's debt took 48% of FY2025 operating profit, limiting fair value to BDT 65–137 (base 105)

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Technical report: trend, RSI, support and resistance, charts

Company profile

The ACME Laboratories Ltd., a pharmaceutical company, engages in the manufacturing, marketing, and distribution of generic pharmaceutical formulation products in Bangladesh. The company offers pharmaceutical products in various therapeutic areas, such as allergic disorders, analgesic, antifribinolytic, anti-infective, antiviral, artificial sweeteners, cardiovascular, central nervous system (CNS), cough and cold, diabetes, eye care and preparations, gastroprokinetic, hepatobiliary, gastrointestinal, gynaecological, hand sanitizers, hormones and steroid, infusion products, musculoskeletal, nasal preparation, respiratory, sex stimulants, skin care, urogenital, and vitamins and minerals. It also provides ayurvedic, and herbal and nutraceutical products. In addition, the company offers its pharmaceutical products in human drugs dosage forms, such as tablets, capsules, dry syrups, creams, ointments, powders, injections, dry powder inhalers, metered dosage inhalers, suppository, eye and nasal drops, liquids in hard gelatin, blow fill seal products, and sachet products; veterinary drugs dosage forms, including bolus, liquids, injections, and water-soluble powders; and premix and herbal drugs dosage forms comprising liquids, capsules, tablets, and creams and ointments. It also exports its products. The ACME Laboratories Ltd. was founded in 1954 and is based in Dhaka, Bangladesh.

Details

Key executives

Contact